Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Interest Expenses (2022 - 2025)

Arcutis Biotherapeutics has reported Interest Expenses over the past 4 years, most recently at $3.0 million for Q4 2025.

  • Quarterly results put Interest Expenses at $3.0 million for Q4 2025, down 45.94% from a year ago — trailing twelve months through Dec 2025 was $12.1 million (down 55.52% YoY), and the annual figure for FY2025 was $12.1 million, down 55.52%.
  • Interest Expenses for Q4 2025 was $3.0 million at Arcutis Biotherapeutics, down from $3.1 million in the prior quarter.
  • Over the last five years, Interest Expenses for ARQT hit a ceiling of $7.8 million in Q4 2023 and a floor of $1.8 million in Q1 2022.
  • Median Interest Expenses over the past 4 years was $6.1 million (2024), compared with a mean of $5.3 million.
  • Biggest five-year swings in Interest Expenses: soared 283.13% in 2023 and later crashed 60.13% in 2025.
  • Arcutis Biotherapeutics' Interest Expenses stood at $6.9 million in 2022, then grew by 12.25% to $7.8 million in 2023, then dropped by 28.48% to $5.6 million in 2024, then tumbled by 45.94% to $3.0 million in 2025.
  • The last three reported values for Interest Expenses were $3.0 million (Q4 2025), $3.1 million (Q3 2025), and $3.0 million (Q2 2025) per Business Quant data.